A newly approved Alzheimer's drug will be available to patients in the coming days, according to its maker. Here are questions experts still have about the drug.
For each category, patients are on a 5-point scale: 0 is normal, 0.5 is questionable dementia and 1, 2 and 3 are mild, moderate and severe stages of dementia, respectively.
At 18 months, patients in the Leqembi group scored on average 1.21 on the clinical dementia scale and the placebo group scored 1.66, a 0.45 difference or 27% slower rate of decline. Donna Wilcock, the assistant dean of biomedicine at the University of Kentucky, said more research is needed. Besides questions about who will benefit the most, there are also questions about how long the drug will benefit patients.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
This Biomarker Can Foreshadow Early Alzheimer's Years Before SymptomsA simple blood test could one day diagnose a rare inherited form of Alzheimer's disease, decades before symptoms of memory loss even appear.
Read more »
National research teams seek Alzheimer's clinical trial participants for new studyRecently, a drug shown to modestly slow the early stages of Alzheimer's was approved by FDA. The drug continues to be studied in larger and longer trials.
Read more »
Korea’s smart lens technology could detect Alzheimer’s at early stagesAlzheimer’s disease affects over 50 million people throughout the world. This new research may be able to detect it early.
Read more »
HRT May Prevent Alzheimer's in High-Risk WomenHormone replacement therapy introduced early during the menopausal transition may protect against Alzheimer's dementia in women carrying the APOE4 gene, new research suggests.
Read more »
Dementia: Brain check-up tool aims to cut risk at any ageYou are never too young to start improving your brain health, an Alzheimer's charity says.
Read more »
Ex-CEO says Biogen shot itself in foot with Alzheimer's drug priceFormer CEO says Biogen 'shot themselves in the foot' by deciding to charge $56,000 for its controversial Alzheimer's drug
Read more »